SynthesisHuman vaccines & immunotherapeutics2017
Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines - A systematic review.
Synthesis in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Evolution and Impact of Hepatitis A Epidemiology in Europe-Systematic Literature Review of the Last 20 Years.Journal of viral hepatitis · 2025Pooled it
- A randomized controlled trial of comparative effectiveness between the 2 dose and 3 dose regimens of hepatitis a vaccine in kidney transplant recipients.Scientific reports · 2021Trial
- Immunogenicity persistence in children of hepatitis A vaccines Healive® and Havrix®: 11 years follow-up and long-term prediction.Human vaccines & immunotherapeutics · 2020Trial
- Hepatitis A vaccination and its public-health impact in routine prevention and outbreak control: a systematic review and meta-analysis.EClinicalMedicine · 2026Review
- Hepatitis A virus endemicity and vaccine policy, India.Bulletin of the World Health Organization · 2026Article
- Therapeutic, preventive, and pathogenetic advances in viral hepatitis.Frontiers in cellular and infection microbiology · 2026Review
- Review
- Current Epidemiological Trends and Public Health Challenges of Hepatitis A Virus Infection in Thailand.The American journal of tropical medicine and hygiene · 2025Review
- Immunogenicity assessment of Hepatitis A-VP1 and Hepatitis B surface antigen (HBsAg) fusion protein: a novel bivalent vaccine candidate.Iranian journal of microbiology · 2025Article
- Update on the global burden of acute viral hepatitis in 2021: addressing health inequalities.Frontiers in public health · 2025Article
- Article
- Article
- Immunogenicity and protective efficacy of a co-formulated two-in-one inactivated whole virus particle COVID-19/influenza vaccine.Scientific reports · 2024Article
- Children With Hepatitis in a Tertiary Care Center in Nepal: A Prospective Observational Study.Global pediatric health · 2024Article
- Hepatitis a Vaccine as Opportunity of Primary Prevention for Food Handlers: A Narrative Review.Vaccines · 2023Review
- Endemicity change of hepatitis A infection necessitates vaccination in food handlers: An Indian perspective.Human vaccines & immunotherapeutics · 2022Review
- Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light.Archives of virology · 2022Article
- Oligomers of hepatitis A virus (HAV) capsid protein VP1 generated in a heterologous expression system.Microbial cell factories · 2022Article
- Burden of disease and associated complications of hepatitis a in children and adults in Mexico: A retrospective database study.PloS one · 2022Observational
- Hepatitis A Outbreak Characteristics: A Comparison of Regions with Different Vaccination Strategies, Spain 2010-2018.Vaccines · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The WHO recommends integration of universal mass vaccination (UMV) against hepatitis A virus (HAV) in national immunization schedules for children aged ≥1 year, if justified on the basis of acute HAV incidence, declining endemicity from high to intermediate and cost-effectiveness. This recommendation has been implemented in several countries. Our aim was to assess the impact of UMV using monovalent inactivated hepatitis A vaccines on incidence and persistence of anti-HAV (IgG) antibodies in pediatric populations. We conducted a systematic review of literature published between 2000 and 2015 in PubMed, Cochrane Library, LILACS, IBECS identifying a total of 27 studies (Argentina, Belgium, China, Greece, Israel, Panama, the United States and Uruguay). All except one study showed a marked decline in the incidence of hepatitis A post introduction of UMV. The incidence in non-vaccinated age groups decreased as well, suggesting herd immunity but also rising susceptibility. Long-term anti-HAV antibody persistence was documented up to 17 y after a 2-dose primary vaccination. In conclusion, introduction of UMV in countries with intermediate endemicity for HAV infection led to a considerable decrease in the incidence of hepatitis A in vaccinated and in non-vaccinated age groups alike.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.